Distress In The Offshore Sector: Alternative Approaches To Restructuring – Hellenic Shipping News Worldwide

The chief executive of Oil & Gas UK, Diedre Michie, has warned that the combination of COVID-19 and the latest oil price collapse, coming so soon after one of the worst downturns in our history, has left the UK oil industry in a paper-thin position.The fall in the oil price has required oil and gas companies operating in the North Sea to announce significant reductions in their exploration and production expenditure. These actions are necessary to maintain cash flows in the short term and ensure the viability of the business in the long term. However, they will also have a negative effect on oil companies supply chains, which have barely recovered from the previous downturn.

We are already seeing a decreasing rate of utilisation in the offshore supply vessel (OSV) market, with many owners approaching their creditors for yet another round of restructurings. While the OSV market is often first in line to take the brunt of any downturn in the offshore sector, there is no question that drilling contractors are also looking anxiously at their backlog with many already anticipating a requirement to review their financing arrangements. New technological advances and industry practices are also accelerating the obsolescence of various types of floating units from drilling rigs and ships to floating accommodation units.

But the main concern that many market commentators are voicing in this current downturn is that prior to the previous collapse of 2015/16 many service providers had been enjoying largely positive income flows with oil prices being sufficiently high to allow them to make significant profits in an industry that was (arguably) already structurally oversupplied at the time. And yet even with this backdrop and the reasonable levels of liquidity achieved during this period, when the collapse came many contractors had to seek Chapter 11 protection or strike deals with their creditors.

For the contractors that did survive the last downturn (and many did not) whether their survival was achieved by way of refinancing or restructuring, or simply by sound financial management over previous years the prevailing feeling has been that large swathes of the offshore sector have remained over-supplied, with contractors holding on to the hope (perhaps rather than the expectation) that the market would at some point recover releasing them from their own financial lockdown. Unfortunately, COVID-19 and the latest oil price collapse has seen many offshore contractors having to retire back to their drawing boards.

One lesson learnt from the last downturn is that, for all its advantages, Chapter 11 is by no means the only, or always the most suitable, option for restructuring especially in the offshore sector. Other alternatives exist that are less expensive and that may also be better at preserving value for creditors and the company. One such alternative that has been used successfully in a number of cases is the scheme of arrangement, which is a restructuring process available under the UK Companies Act through which a company can propose a compromise or arrangement with its creditors. Schemes of arrangement are also part of the law in jurisdictions whose legal systems derive from English law, such as Singapore, Hong Kong, Bermuda and the Cayman Islands. Schemes are more streamlined and flexible than Chapter 11, while also offering a mechanism with extraterritorial reach.

Whilst a scheme of arrangement does not normally involve an insolvency moratorium (although the Singapore variant can include this feature), it does offer a process through which a companys debts can be restructured and dissenting creditors crammed down. Bibby Offshore (through a UK scheme) and Ocean Rig (through a Cayman scheme) showed how this process can be utilised in conjunction with other restructuring tools (such as centre of main interest (COMI) shifts and Chapter 15 recognition) to effectively restructure debt governed by New York law and of companies incorporated in jurisdictions other than the jurisdiction of the scheme itself.

Inevitably the long-term goal must be that whatever pain the industry has to endure now must give rise to a sustainable and competitive, but still profitable, market place. Unfortunately, as it has proven in the past, the offshore market suffers the same vagaries as any other maritime sector with a boom bust and back again cycle and the inevitably painful penchant for oversupply that this can bring.Source: Watson Farley & Williams LLP

Read the original:

Distress In The Offshore Sector: Alternative Approaches To Restructuring - Hellenic Shipping News Worldwide

W&T Offshore Provides Operational Update and Announces Timing of First Quarter Earnings Reporting and Additional Natural Gas Hedges – Yahoo Finance

HOUSTON, April 30, 2020 (GLOBE NEWSWIRE) -- W&T Offshore, Inc. (WTI) (W&T or the Company) today provided an operational update and announced that as provided under an SEC Order dated March 25, 2020, it intends to temporarily delay filing its first quarter 2020 Form 10-Q due to circumstances related to COVID-19, within the time limits allowed by the SEC Order. W&T also disclosed additional natural gas hedges.

Key highlights included:

Tracy W. Krohn, W&T's Chairman and Chief Executive Officer, commented, This is an extraordinary time for energy companies with the drastic fluctuations in supply and demand which has been compounded by the global COVID-19 pandemic. With that said, as provided by the SEC, we are temporarily delaying the filing of our 10-Q due to matters related to the pandemic.

This is one of the most volatile and challenging markets I have seen in the past 40 years, but our overall strategy remains unchanged with our focus steadfastly on preserving and generating cash flow. While we have significantly reduced our expected 2020 capital spend by suspending our drilling activity, we remain confident in the long-term viability of our substantial inventory of drilling opportunities. We have proactively curtailed production on selected oil-weighted fields operated by the Company in this weak price environment, but maintain production at our Mahogany field and our key natural gas fields at our Mobile Bay complex. We have also received notification of potential shut-in production at non-operated properties. We will continue to monitor the oil markets to see if additional shut-ins are appropriate. From an expense standpoint, we are well on our way to implementing meaningful costs savings. We have an exceptional operational team in place, a diverse asset base with good-quality natural gas and oil fields and a strong hedge book, all of which provide us with the ability to weather uncertain commodity price environments.

Operational UpdateDuring the first quarter of 2020, W&Ts production averaged 53,553 barrels of oil equivalent per day (Boe/d), or 4.9 million Boe (48% liquids), near the high end of the Companys first quarter guidance range, reflecting a 61% increase from the first quarter of 2019 and slightly higher than the fourth quarter of 2019.

During the first quarter of 2020, the Company performed one recompletion and four workovers that in total added approximately 700 net Boe/d to production. W&T currently plans to continue to perform recompletions and workovers that meet economic thresholds.

As of April 30, 2020, W&T has temporarily shut-in production of approximately 3,300 Boe/d in selected oil-weighted fields operated by the Company but maintains production at its Mahogany field and its key natural gas fields at our Mobile Bay complex. The Company continues to monitor the market for the sale of its production as well as commodity prices and may consider additional curtailments of its operated production in the future, if market conditions warrant. W&T also received notice of production at non-operated fields that may potentially be shut-in by its other working interest owners. Those third-party curtailments are currently estimated to total approximately 3,400 Boe/d net to W&T. W&T is implementing 15% to 25% reductions in lease operating expenses without compromising safety or operational capabilities and reviewing G&A costs for additional savings. As a result of the production curtailments, proactive efforts to continually reduce costs in the lower price environment and ongoing uncertainty in the commodity markets, the Company has decided to withdraw the annual guidance it provided earlier this year and will provide such guidance again in the future when there is more stability in oil and gas markets.

Response to COVID-19 PandemicW&T is committed to the health and safety of all its employees and contractors and has taken proactive steps to ensure their continued safety in its response to the COVID-19 pandemic. At W&Ts corporate offices, the Company mandated a work-from-home policy as of March 23, 2020 and assured that all employees had the ability to continue performing their work duties remotely. W&T continues to monitor the situation and will follow the advice of government and health leaders regarding fully reopening its corporate offices.

Story continues

The Company instituted screening of all personnel prior to entry to heliports and shorebases as well as its two Alabama gas plants, which includes a questionnaire and temperature check. The Company conducts daily temperature screenings at all offshore facilities and implemented procedures for distancing and hygiene at its field locations.

Timing of Reporting First Quarter ResultsThe Company announced that as provided under an SEC Order dated March 25, 2020, it intends to temporarily defer filing its first quarter 2020 Form 10-Q due to circumstances related to COVID-19, within the time limits allowed by the SEC Order. A Form 8-K will be filed with the SEC under the guidelines provided by the SEC. W&T intends to issue its first quarter 2020 earnings release, file its Form 10-Q and conduct its quarterly conference call on or before the end of the 45-day extension period on June 25, 2020.

Hedging UpdateIn the first quarter of 2020, W&T added natural gas Henry Hub costless collars on 40,000 thousand cubic feet per day (Mcf/d) of natural gas production for the period April 1, 2020 through December 31, 2022 with a floor of $1.83 per Mcf and a ceiling of $3.00 per Mcf. The Company also added Henry Hub costless collars on 20,000 Mcf/d of production for the period January 1, 2021 through December 31, 2021 with a floor of $2.17 and a ceiling of $3.00, and on 10,000 Mcf/d of production for the same period with a floor of $2.20 and a ceiling of $3.00.

W&T recently added Henry Hub costless collars on 10,000 Mcf/d of production for the period May 1, 2020 through December 31, 2020 with a floor of $1.75 and a ceiling of $2.58. A listing of the Companys current outstanding derivative positions is included in the tables below as well as in the Investor Relations section of W&Ts web site under the Financial Info tab.

About W&T OffshoreW&T Offshore, Inc. is an independent oil and natural gas producer with operations offshore in the Gulf of Mexico and has grown through acquisitions, exploration and development. The Company currently has working interests in 51 producing fields in federal and state waters and has under lease approximately 815,000 gross acres, including approximately 595,000 gross acres on the Gulf of Mexico Shelf and approximately 220,000 gross acres in the Gulf of Mexico deepwater. A majority of the Companys daily production is derived from wells it operates. For more information on W&T, please visit the Companys website at http://www.wtoffshore.com.

Forward-Looking and Cautionary Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements reflect our current views with respect to future events, based on what we believe are reasonable assumptions. No assurance can be given, however, that these events will occur. These statements are subject to risks and uncertainties that could cause actual results to differ materially including, among other things, market conditions, oil and gas price volatility, uncertainties inherent in oil and gas production operations and estimating reserves, unexpected future capital expenditures, competition, the success of our risk management activities, governmental regulations, the continued impact of responses to COVID-19, uncertainties and other factors discussed in W&T Offshores Annual Report on Form 10-K for the year ended December 31, 2019 and subsequent Form 10-Q and Form 8-K reports found at http://www.sec.gov or at our website at http://www.wtoffshore.com under the Investor Relations section. Investors are urged to consider closely the disclosures and risk factors in these reports.

Follow this link:

W&T Offshore Provides Operational Update and Announces Timing of First Quarter Earnings Reporting and Additional Natural Gas Hedges - Yahoo Finance

North Sea welcomes Health Protection Scotland guidance on preventing Covid-19 offshore – News for the Oil and Gas Sector – Energy Voice

The UKs oil and gas industry has welcomed the publication of fresh guidance on managing Covid-19 cases offshore.

Health Protection Scotland has produced a 20-page document setting out how helicopter companies, duty holders and medics can manage and prevent an outbreak on oil and gas installations.

It comes as the North Sea has seen confirmed cases across several offshore platforms, with dozens more people suspected to have been infected but not confirmed.

Step Change in Safety (SCIS) said it was pleased to see the publication after initial guidance from HPS lacked the detail and clarity to address the industrys specific needs.

Industry body Oil and Gas UK also worked to produce the document, which goes into points including PPE requirements, quarantine measures and dealing with cases that develop while helicopters are in transit.

The guidance can be read here.

SCIS executive director Steve Rae said: We are pleased to hear that the HPS guidance has now been officially published.

We realised from the onset of the lockdown that the UK Government and HPSs mainstream initial guidance lacked the detail and clarity to address our industrys specific needs.

To this end, we took the proactive approach of establishing a two-way communication conduit so that we could receive first-hand the concerns of our workforce and respond accordingly.

We have been collaborating with OGUK (Oil and Gas UK) since the onset of the COVID-19 pandemic to ensure the information we are making available to the workforce is consistent, timely and factual.

We will continue to do so as the safety and wellbeing of our workforce remains of paramount importance to us at this difficult and challenging time.

A survey published last week by offshore unions highlighted workers concerns around the industrys response to the outbreak, from sick pay to the use of PPE.

OGUKs HSE director Trevor Stapleton said: OGUKs Pandemic Steering Group worked alongside the HSE, Public Health England and Health Protection Scotland to draft and publish this guidance which helps demonstrate and give clarity to industrys proactive and comprehensive response to the COVID19 pandemic.

OGUK together with wider industry continues to do everything we can to protect the health and welfare of our workforce and we will review and evolve industry guidance as we learn more about this virus.

The rest is here:

North Sea welcomes Health Protection Scotland guidance on preventing Covid-19 offshore - News for the Oil and Gas Sector - Energy Voice

Equinor hires MMT to probe US offshore wind sites – reNEWS

Equinor has awarded a contract to MMT to conduct geophysical studies at the developers offshore wind lease area off New England.

Survey operations will begin late summer 2020 and will run until the second quarter of 2021.

The contract covers high resolution geophysical, benthic surveys and shallow subsurface surveys for the planning and engineering of Equinors lease area off New England.

MMT will use its Stril Explorer vessel, which is equipped with the Surveyor Interceptor SROV.

MMT developed the Surveyor Interceptor with Reach Subsea to reduce the time it takes to carry out offshore surveys.

The technology will significantly increase the operational window, cut operation time, and reduce the impact on the surrounding wildlife by reducing the noise in the water column, MMT said.

The method will also allow all surveys to be conducted from a single vessel rather than the standard two-vessel deployment.

The Surveyor Interceptor will be modified to host more sensors, to achieve all the offshore wind data requirements Equinor requires, MMT said.

MMT chief executive Per-Olof Sverlinger said: This award is strategically important as MMT/Reach has been preparing to support our clients in the US offshore wind industry for more than two years now.

We have a long experience from the renewables segment in Europe and developers have shown interest in using our professional support in the US market. They know what we can deliver and we know their requirements on both a safe and efficient operation and the quality of deliverables.

Reach Subsea chief executive Jostein Alendal added: This major award is a testament to the combined capabilities of Reach and MMT, our track record worldwide, and our ability to develop innovative solutions.

To be in the technological forefront demands a good portion of stamina and it is encouraging for the whole team to get this recognition from a leading operator like Equinor.

Here is the original post:

Equinor hires MMT to probe US offshore wind sites - reNEWS

Diamond Offshore Drilling (DO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? – Yahoo Finance

The market expects Diamond Offshore Drilling (DO) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2020. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.

The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may move lower.

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

Zacks Consensus Estimate

This offshore oil and gas drilling contractor is expected to post quarterly loss of $0.79 per share in its upcoming report, which represents a year-over-year change of -49.1%.

Revenues are expected to be $217.98 million, down 6.7% from the year-ago quarter.

Estimate Revisions Trend

The consensus EPS estimate for the quarter has been revised 13.43% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings Whisper

Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for Diamond Offshore Drilling?

For Diamond Offshore Drilling, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +1.76%.

Story continues

On the other hand, the stock currently carries a Zacks Rank of #3.

So, this combination indicates that Diamond Offshore Drilling will most likely beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?

While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that Diamond Offshore Drilling would post a loss of $0.66 per share when it actually produced a loss of $0.45, delivering a surprise of +31.82%.

Over the last four quarters, the company has beaten consensus EPS estimates three times.

Bottom Line

An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Diamond Offshore Drilling appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportDiamond Offshore Drilling, Inc. (DO) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

View post:

Diamond Offshore Drilling (DO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance

Riviera – Events – Offshore Wind Webinar Week – Riviera Maritime Media

Be sure to join us for Offshore Wind Webinar Week

Beginning Monday 8 June, we will be holding a series of daily webinars, meticulously researched and organised to address offshore support vessel operations and associated technologies with the maritime professionals you want to hear from. The webinars are designed to strike the right balance between transmission of key information and interaction with the expert panel assembled.

Our discussions are focused, cover the advertised subjects, and deliver registrants actionable insights.

Should you wish to join one of our expert panels please contact Bill Cochrane.

Please join us for any or all of the following:

Date: Monday 8 June - Time: 09:00-09:45 BST

Register now

The Walk-to-Work (W2W) sector is set for growth with offshore wind turbine installations forecast to treble through to 2030. The challenge for industry is managing the greater range of risks that go hand-in-hand with transferring personnel across a moving gangway in different theatres of operations. Our panel will use case studies to model what needs to be considered when preparing for the W2W opportunities and challenges ahead.

Join us as we cover

Date: Wednesday 10 June - Time: 09:00-09:45 BST

Register now

The race is on to reduce emissions and achieve carbon neutrality throughout the supply chain. Offshore wind vessel owners are considering - and investing - in new types of propulsion, innovative designs and hullforms. High-tech CTVs and SOVs are also attracting interest and orders. Dont get left behind! Our panel of industry experts will assess the available options and detail whats required to join and stay at the head of the pack.

Join us as we cover

Date: Thursday 11 June - Time: 16:00-16:45 BST

Register now

Offshore windfarm development in the United States holds considerable potential and is one of the best prospects for new opportunities. What North American developers are asking is how to bring European experience to the US and customise it for local conditions and regulations. Our webinar will bring the relevant parties together to provide the advice you need and respond to your questions on this significant emerging market.

Join us as we cover

See the article here:

Riviera - Events - Offshore Wind Webinar Week - Riviera Maritime Media

COVID-19 | Resetting the offshore industry to help Indias job market – Moneycontrol.com

Kavita Dwivedi and Badri Narayanan Gopalakrishnan

One of the key industries that set the Indian economy into the growth path in the last decade has been offshoring. With COVID-19-induced lockdowns in different parts of the world for more than two months now, Indian offshoring industry needs to strategise and realign its operations.

Experts have been predicting a structural and fundamental change in the kind of jobs available in India within the offshoring sector by 2022. Industry 4.0, increased innovation, automation, robotics, increased data protection laws such as General Data Protection Regulation (GDPR), growing demand for artificial intelligence (AI) and machine learning (ML) would lead to these changes. However, now with the COVID-19 impact, the way the world operates is going to witness a change.

The Government of India together with industry bodies and leaders who shaped Indias offshoring industry and startups can look at using this challenge as an opportunity, form strategies to both import foreign companies and jobs to India and also export jobs after the pandemic. This gives our political and industrial leaders some lead time to attract MNCs to come and set up their business operations in areas of IT, ITES, banking, telecom, healthcare, education, travel and tourism, FMCGs, etc.

It may be early days, but India is emerging relatively positive on the world stage during this COVID era. As a nation, we are collectively fighting the virus with a positive intent and discipline, serving as an example to rest of the world. This positivity can help us in creating a favourable environment for industries to come and expand in India.

The Indian offshoring industry bigwigs such as Infosys, TCS, Cognizant, and Capgemini, would need to redefine the way they operate. This is the time to reskill their workforce and deploy them in the new-age jobs. Indias $150 billion outsourcing industry was slowly hitting the tipping point even before COVID-19. The industry lauded for its ability to put India on the map as a destination for high-quality, low-cost technology skills, fast turnaround and for being an engine of wealth and job creation would need to rejig its way and start a second wave of new-age skilled jobs in India.

According to a report by Gartner, more than 80 percent of logistics leaders globally planned to increase their outsourcing budget by more than 5 percent by 2020. One of the reasons for this is that outsourcing their logistics helped them a lot by meeting or exceeding the end-to-end (E2E) supply chain and overall business objectives.

India remains the leading country to outsource as perTholons Top 50 Digital NationsandAT Kearney Global Services Location Indexof 2019. The country also has 14 super cities listed in the Tholons report.Its time for central, state and industry leadership to plan and market these cities as preferred destinations for such outsourcing operations. Indias 100 Smart Cities project should help us in identifying the cities that can be marketed as top offshoring destinations. This will help boost our economy both on the financial side and also will give some respite to the problem of unemployment.

The High Level Strategic Group (HLSG) set up by the Centre estimates a net workforce shortfall of 32-39 million by 2020 in developed countries. The same report goes on to assert that contribution of remote services alone, which is the main focus of this report, will be $133-315 billion of additional revenue flowing into the country and the addition of 10-24 million jobs (direct and indirect) by 2020.

It also adds that importing customers into India (medical tourism, educational services, leisure tourism) could add $6-50 billion in revenue and create 10-48 million jobs by 2020. The HLSG estimates that through remote services and the importation of customers India could enhance year-to-year GDP growth by up to 1.5 percent over current growth rates, most of which (~80-85 percent) would be through remote services.

This is the right time for the government, industry bodies and leaders of offshoring and IT industry to form a strategy to position India as the most favourable destination for offshoring by providing ease of business, marketing it the right way and training Indians on advanced/skill sets that can support the growth trajectory and optimise costs of Industry 4.0 for global companies.

A downside that remains, however, is that offshoring industry may be heavily hit by the global recession.

Moneycontrol Ready Reckoner

Now that payment deadlines have been relaxed due to COVID-19, the Moneycontrol Ready Reckoner will help keep your date with insurance premiums, tax-saving investments and EMIs, among others.

First Anniversary Offer: Subscribe to Moneycontrol PROs annual plan for 1/- per day for the first year and claim exclusive benefits worth 20,000. Coupon code: PRO365

Link:

COVID-19 | Resetting the offshore industry to help Indias job market - Moneycontrol.com

Stryker beats The Street on Q1 results, warns of significant COVID-19 impact – Mass Device

Stryker(NYSE:SYK) shares dropped slightly today on first-quarter results that came in ahead of the consensus forecast.

The Kalamazoo, Mich.-based orthopedic device company posted profits of $493 million, or $1.30 per share, on sales of $3.6 billion for the three months ended March 31, 2020, for a 19.7% bottom-line gain on sales growth of 2%.

Adjusted to exclude one-time items, earnings per share were $1.84, 15 ahead of Wall Street, where analysts were looking for sales of $3.4 billion.

According to a news release, COVID-19 significantly impacted Strykers consolidated net sales in a negative way, resulting in unit volume growth rates that were lower than expected across all segments.

On the companys earnings call, Stryker VP of strategy & IR Katherine Owen noted that between 40% and 50% of its global revenue includes elective procedures that can be deferred. These kinds of procedures have practically come to a halt everywhere as attention is turned to the COVID-19 crisis.

During April alone, Strykers orthopedics and spine sales were down approximately 65%, while its medical-surgical and neurotechnology businesses posted 25% declines.

And as patients who have deferred surgical procedures begin to return over the coming weeks and months, we will work with our customers to help meet the expected demand. On behalf of the Stryker leadership team, I would like to offer my thanks to our thousands of employees around the globe and to the caregivers and first responders for their tremendous efforts in dealing with this health crisis.

Stryker previously reported an expected organic sales growth for 2020 to be in the range of 6.5% to 7.5% and its full-year earnings per share to range between $9.00 and $9.20. However, in March, the company withdrew its guidance amid the uncertainties caused by the coronavirus pandemic.

SYK shares were down -1.4% at $183.92 per share in mid-morning trading today. MassDevices MedTech 100 Index which includes stocks of the worlds largest medical device companies was down 1.3%.

Originally posted here:

Stryker beats The Street on Q1 results, warns of significant COVID-19 impact - Mass Device

Morgan Stanley Maintains Their Buy Rating on Stryker (SYK) – Smarter Analyst

Morgan Stanley analyst David Lewis maintained a Buy rating on Stryker (SYK) today and set a price target of $215.00. The companys shares closed last Friday at $179.73.

According to TipRanks.com, Lewis is a 5-star analyst with an average return of 8.3% and a 63.1% success rate. Lewis covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Zimmer Biomet Holdings, and Baxter International.

Currently, the analyst consensus on Stryker is a Moderate Buy with an average price target of $202.93, which is a 5.3% upside from current levels. In a report released yesterday, BTIG also maintained a Buy rating on the stock with a $213.00 price target.

See todays analyst top recommended stocks >>

The company has a one-year high of $226.31 and a one-year low of $124.54. Currently, Stryker has an average volume of 2.42M.

Based on the recent corporate insider activity of 65 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SYK in relation to earlier this year. Most recently, in March 2020, Srikant Datar, a Director at SYK bought 1,000 shares for a total of $59,700.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stryker Corp. engages in providing medical technology products and services. It operates through the following segments: Orthopaedics, MedSurg and Neurotechnology and Spine. The Orthopaedics segment provides reconstructive and trauma implant systems. The Medsurg segment deals with surgical equipment and navigation systems, endoscopy, patient handling, and reprocessed medical devices. The Neurotechnology and Spine segment pertains to spinal implants and neurovascular products. The company was founded by Homer H. Stryker in 1941 and is headquartered in Kalamazoo, MI.

More here:

Morgan Stanley Maintains Their Buy Rating on Stryker (SYK) - Smarter Analyst

The scientist told about the dangers of smartphones during a pandemic coronavirus – The Times Hub

The use of modern gadgets, primarily smartphones in a pandemic COVID-19 may threaten not only physical but also psychological well-being. This statement was made by zavlaboratoriey AI and Neurotechnology REU them. Plekhanov Timur Sadykov.

Smartphones, the specialist says dangerous primarily because they are breeding grounds for bacteria and infection. Constantly being in use in human hands, the device actively collects on itself the bacteria and infection, thus when using it, people often touch this device to the ears and to the face as a whole, said the scientist. In terms of the danger of infection, the gadget needs regular disinfection, he recalls. With this, you can use, for example, wipes impregnated with a composition based on isopropyl alcohol which will not harm the protective coating of the display.

Separately, the expert drew attention to the fact that uncontrolled frequent use of smartphone and other devices, especially when it comes to children, can harm the body posture and vision.

Visit link:

The scientist told about the dangers of smartphones during a pandemic coronavirus - The Times Hub

COVID19 Update: Facial Recognition Market 2020: Size, Share, Application, Regional Outlook, Competitive Strategies Analysis and Forecasts To 2025 -…

The Facial Recognition Market report includes overview, which interprets value chain structure, industrial environment, regional analysis, applications, market size, and forecast. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally.

Top Leading Key Players are:

NEC Corporation, Aware, Inc., Ayonix Corporation, Cognitec Systems GmbH, Gemalto NV, Animetrics, Daon, Id3 Technologies, Idemia, Innovatrics, Megvii, Neurotechnology, NVISO SA, StereoVision Imaging, Inc., Techno Brain Group, etc.

Get Sample Copy of this Report @ https://www.adroitmarketresearch.com/contacts/request-sample/908

This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. The report provides an overall analysis of the market based on types, applications, regions, and for the forecast period from 2020 to 2025. It also offers investment opportunities and probable threats in the market based on an intelligent analysis.

This report focuses on the Global Facial Recognition Market trends, future forecasts, growth opportunities, key end-user industries, and market players. The objectives of the study are to present the key developments of the market across the globe.

Browse the complete report @ https://www.adroitmarketresearch.com/industry-reports/facial-recognition-market

Global Facial Recognition Market is segmented based by type, application and region.

Based on Type, the Market has been segmented into:

by Technology (2D facial recognition, 3D facial recognition, facial analytics recognition), Application, End User (BFSI, media & entertainment, telecom & IT, Government & Defense, Healthcare, Retail & E-commerce)

Based on application, the Market has been segmented into:

By Application, End User (BFSI, media & entertainment, telecom & IT, Government & Defense, Healthcare, Retail & E-commerce)

The report provides useful insights into a wide range of business aspects such as pillars, features, sales strategies, planning models, in order to enable readers to gauge market scope more proficiently. Furthermore, the report also sheds light on recent developments and technological platforms, in addition to distinctive tools, and methodologies that will help to propel the performance of industries.

The Facial Recognition Market report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Facial Recognition market analysis is provided for the international market including development history, competitive landscape analysis, and major regions development status. Furthermore, Market size, the revenue shares of each segment and its sub-segments, as well as forecast figures are also covered in this report. This report provides detailed study on the market size, share, growth, trends, as well as industry analysis.

For Any Query on the Facial Recognition Market: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/908

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a Markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable Market insights to help create opportunities that increase their revenues. We follow a code- Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 972-362 -8199/ +91 9665341414

Here is the original post:

COVID19 Update: Facial Recognition Market 2020: Size, Share, Application, Regional Outlook, Competitive Strategies Analysis and Forecasts To 2025 -...

Five UC San Diego Professors Elected to National Academy of Sciences – UC San Diego Health

Clockwise from top left, Dmitri Basov, Lawrence Goldstein, Terence Hwa, Clifford Kubiak, Kimberly Prather

The National Academy of Sciences elected five professors affiliated with the University of California San Diego to membership in the prestigious National Academy of Sciences, one of the highest honors bestowed on U.S. scientists and engineers.

UC San Diego faculty members Dmitri Basov, Lawrence Goldstein, Terence Hwa, Clifford Kubiak, and Kimberly Prather whose work spans fields ranging from medicine and biological sciences to atmospheric chemistry and physics were recognized Monday in recognition of their distinguished and continuing achievements in original research, according to the Academy. They were among 120 American scientists and 26 international members named this year.

For a young institution such as ours, having five professors inducted into the National Academy of Sciences speaks volumes of the innovative and visionary nature of this university and our well-respected and accomplished faculty, said UC San Diego Chancellor Pradeep K. Khosla. I am proud to see the career accomplishments of these five professors recognized on such a distinguished national platform, alongside the countrys other leading researchers.

This brings the total number of National Academy of Sciences members from UC San Diego to 86.

Dmitri Basov is an affiliated UC San Diego professor in the Department of Physics, where he served as chair between 2010 and 2015. He is also a Higgins professor in the Department of Physics at Columbia University, where he is the principal investigator of the Basov Infrared Laboratory, the director of the DOE Energy Frontiers Research Center on Programmable Quantum Materials and co-director of the Max Planck Society New York Center for Nonequilibrium Quantum Phenomena. His research interests include physics of quantum materials, superconductivity, two-dimensional materials and infrared nano-optics. Basov has received numerous prizes and awards including a Sloan Fellowship (1999), the Genzel Prize (2014), a Humboldt research award (2009), the Frank Isakson Prize, American Physical Society (2012), Moore Investigator (2014), the K.J. Button Prize (2019) and the Vannevar Bush Faculty Fellowship (U.S. Department of Defense, 2019).

Basov earned his PhD at the Lebedev Physical Institute of the Russian Academy of Sciences (1991). He served as postdoctoral research associate at McMaster University (1992-96) and as an assistant physicist at Brookhaven National Laboratory (1996) before joining UC San Diego.

Lawrence Goldstein, PhD, is Distinguished Professor in the Department of Cellular and Molecular Medicine and Department of Neurosciences in the UC San Diego School of Medicine. He founded and directed the UC San Diego Stem Cell Program and the Sanford Stem Cell Clinical Center at UC San Diego Health and is founding scientific director of the Sanford Consortium for Regenerative Medicine. He was instrumental in the development and passage of Proposition 71 in 2004, which created an unprecedented $3 billion fund and infrastructure for stem cell medical research in California.

For more than 25 years, Goldsteins research focus has been to unravel how molecular motors interact with and control the behavior of axonal vesicles in neurons, and how defects in these processes underlie neurological conditions, such as Alzheimers disease (AD).In 2012, his lab was the first to create stem cell-derived in vitro neurons of sporadic and hereditary AD, giving researchers a much-needed method for studying the diseases causes and pathologies and a new tool for developing and testing drugs to treat a disorder that afflicts 5.4 million Americans.

More recently, this work has led to the identification of new cellular targets in AD drug development and a deeper understanding of AD genetics and disease progression. He is among the nations leading scientific figures in promoting AD research and evidence-based treatments.

Terence Hwa is the Presidential Chair and Distinguished Professor in the Department of Physics with a joint appointment in the Division of Biological Sciences. Trained in theoretical physics, Hwa launched a biology wet-lab 15 years ago and developed a unique quantitative approach to studying bacterial physiology. During this time, the Hwa Research Group established a number of bacterial growth laws and formulated a principle of proteomic resource allocation. This line of study culminated in a theory of bacterial growth control, accurately predicting bacterial behaviors and gene expression for a variety of environmental and genetic perturbations, and resolving a number of long-standing mysteries in microbiology. Hwas research team continues to extend its quantitative approaches to characterize bacterial species singly and in consortium, to uncover underlying principles governing the spatiotemporal dynamics of microbial communities.

Hwa is a champion of interdisciplinary research. In 2001, he launched an extended program at the Kavli Institute of Theoretical Physics in Santa Barbara, which has been regarded as a watershed event in bringing physicists to post-genome biology. He is also the founder and co-director of the Quantitative Biology specialization program at UC San Diego. Hwa received fellowships and awards from the Sloan, Beckman, Guggenheim and Burroughs-Wellcome Foundations, and is a Fellow of the American Physical Society and the American Academy of Microbiology. Hwa received his PhD in physics from MIT. After postdoctoral research at Harvard University in condensed-matter physics, he joined UC San Diegos physics faculty in 1995.

Clifford Kubiak is a Distinguished Professor and former chair of the Department of Chemistry and Biochemistry, who holds the Harold C. Urey Chair in Chemistry. His Kubiak Research Group at UC San Diego is especially known for its work on developing catalysts for the electrochemical reduction of carbon dioxide. Kubiak is also a fellow of the American Academy of Arts and Sciences and the American Chemical Society (ACS). He has received several awards including the prestigious ACS Award in Organometallic Chemistry (2018), the Tolman Medal (2018), the Basolo Medal for Outstanding Research in Inorganic Chemistry (2015), the Inter-American Photochemical Society, Award in Photochemistry (2013) and the ACS Award in Inorganic Chemistry (2012). Kubiak has held visiting appointments at Tohoku University, University of Chicago and University of Erlangen, and he was a visiting associate in chemistry at the Joint Center for Artificial Photosynthesis at Caltech. He has served on the Editorial Advisory Boards of Accounts of Chemical Research, Inorganic Chemistry and Materials Science in Semiconductor Processing. He is the author of more than 290 scientific articles.

Before joining UC San Diego in 1998, Kubiak was a faculty member at Purdue University (1982-98). Before that he was a postdoctoral associate with Mark S. Wrighton at MIT (1980-81). He received his PhD in chemistry from the University of Rochester (1980), where he worked with Richard Eisenberg.

Kimberly Prather is a Distinguished Professor who holds a joint appointment between UC San Diegos Scripps Institution of Oceanography and the Department of Chemistry and Biochemistry. Prathers research focuses on understanding the influence of atmospheric aerosols on clouds, human health, and climate. Early in her career, she developed a technique known as aerosol time-of-flight mass spectrometry that is widely used in atmospheric field studies around the world to determine the origin and chemistry of aerosols. She is the founding director of the National Science Foundation Center for Aerosol Impacts on Chemistry of the Environment (CAICE), the largest federally funded center in the history of UC San Diego. CAICE researchers replicate ocean/atmosphere interactions in a laboratory setting to study the influence of ocean biology on atmospheric chemistry, clouds, and climate.

Prather joined UC San Diego in 2001. She was elected as a member of the American Academy of Arts and Sciences and a fellow of the American Geophysical Union in 2010. In 2019, she became the first woman at UC San Diego to be elected as a member of the National Academy of Engineering. Previously this year, she won the 2020 Frank H. Field and Joe L. Franklin Award for Outstanding Achievement in Mass Spectrometry from the American Chemical Society. She received her PhD in chemistry from the University of California, Davis.

Visit link:

Five UC San Diego Professors Elected to National Academy of Sciences - UC San Diego Health

Four UTSW Researchers Named to The National Academy of Sciences – D Magazine

Four UT Southwestern Medical Center scientists have been elected to the The National Academy of Sciences, one of the top honors for American scientists.

Peer scientists selected Sean Morrison, Kim Orth, Michael Rosen, and Sandra Schmid for their original research and achievements. UT Southwestern now has 25 members of the academy, the most of any institution in Texas.

Election to the prestigious National Academy of Sciences recognizes the pioneering contributions these scientists have made to advance our understanding of basic cellular function and molecular processes with application to addressing a broad spectrum of unmet medical needs including cancer and treatments for bacterial infections, said Dr. Daniel K. Podolsky, President of UT Southwestern Medical Center via release. Their election enriches the National Academy of Sciences efforts to provide data and advice on the nations most critical issues in science, health, and medicine.

Morrison is the Director of the Childrens Medical Center Research Institute (CRI) at UT Southwestern and Professor of Pediatrics and has worked in the fields of stem cell biology and cancer, and has created new methods to purify stem cells and allow them to persist and regenerate after injury. This recognizes, first and foremost, the work of many talented people over the years in my lab, most of whom have now gone on to their own laboratories at UT Southwestern and other institutions. Many of the key insights for the important discoveries that were made came from them so this really recognizes their work. Id also like to acknowledge all my colleagues, all of you at UT Southwestern and at Childrens Health, for the incredible environment that you created for science, Morrison said via release.

Orth is a Professor of Molecular Biology and Biochemistry and has discovered biochemical mechanisms behind many bacterial infections, revealing how pathogens use host cells for their own benefit. I want to thank you all for this wonderful celebration, even though we have to Zoom . Thanks to this amazing institution, UT Southwestern, the wonderful administration including Drs. (Daniel) Podolsky and (David) Russell and the other administrators and staff. As (Chair of Molecular Biology) Eric Olson said, I have moved up the ranks here, starting as a technician, to a student, a postdoc, and now Professor, Orth said via release. And this path has driven my success. Another major key to my success is all of the talented people that have worked in my lab and my mentors, friends, collaborators, and, of course, my family.

Rosen is the Chair of Biophysics and Professor in the Cecil H. and Ida Green Comprehensive Center for Molecular, Computational, and Systems Biology, and investigates how cells compartmentalize processes without the use of membranes. When we began our work on phase separation about a decade ago, it really was not obvious at all whether this was going to be some weird, esoteric little thing that a few proteins did or (if) it was going to become a more general principle in biology. So it wasa tremendous risk that many of us took in making a move in this new direction. More than anything, I want to thank the various people whojoined me in taking this great risk a decade ago that I think has proved to be very much worthwhile, Rosen said via release.

Schmid is the Professor and Chair of Cell Biology and is recognized for her work on endocytosis, or how cells absorb nutrients and other molecules, including the major pathway for uptake within the cell. Ive been lucky to start and end my academic career at two unique institutions, Schmid said via release. As a PhD student in the early 80s, I was supported and challenged by my peers and faculty in the Biochemistry department at Stanford to ask important questions and do the most impactful research. Over decades, the leadership at UT Southwestern has inspired, supported and celebrated the very best research creating a collegial culture that breeds success.

This important recognition by their peers reflects the breadth and quality of research underway at UT Southwestern, and serves as inspiration for new generations of trainees and scientists to carry on the tradition of discovery that is the hallmark of distinguished academic medical centers, said Dr. W. P. Andrew Lee., Executive Vice President for Academic Affairs, Provost and Dean of UT Southwestern Medical School via release.

Read this article:

Four UTSW Researchers Named to The National Academy of Sciences - D Magazine

Five HMS Faculty Elected to National Academy of Sciences – Harvard Medical School

Five scientists have been elected to the National Academy of Sciences in recognition of their distinguished and continuing achievements in original research. They are among 120 members and 26 international members elected.

The newly elected members from HMS are:

Joel Habener, professor of medicine and chief of the laboratory of molecular endocrinology at Massachusetts General Hospital

Judy Lieberman, professor of pediatrics and chair of cellular and molecular medicine at Boston Children's Hospital

Margaret Livingstone, the Takeda Professor of Neurobiology in the Blavatnik Institute

Olivier Pourqui, the Frank Burr Mallory Professor of Pathology at Brigham and Women's Hospital and professor of genetics in the Blavatnik Institute

Suzanne Walker, professor of microbiology in the Blavatnik Institute

Get more HMS news here

Other Harvard faculty elected this year include: Dennis Gaitsgory, professor of mathematics, Michael Kremer, the Gates Professor of Developing Societies in the Department of Economics and Wilfried Schmid, professor of mathematics.

The National Academy of Sciences is a nonprofit institution that was established under a congressional charter signed by President Abraham Lincoln in 1863. It recognizes achievement in science by election to membership, andwith the National Academy of Engineering and the National Academy of Medicineprovides science, engineering, and health policy advice to the federal government and other organizations. The National Academy of Sciences charter commits the Academy to provide scientific advice to the government whenever called upon by any government department. The NAS is committed to furthering science in America, and its members are active contributors to the international scientific community.

Read more:

Five HMS Faculty Elected to National Academy of Sciences - Harvard Medical School

Old Drugs May Find a New Purpose: Fighting the Coronavirus – The New York Times

In the early 1950s, psychiatrists began treating schizophrenia with a new drug called chlorpromazine. Seven decades later, the drug is still used as an anti-psychotic.

But now scientists have discovered that the drug, also known as Thorazine, can do something entirely different. It can stop the new coronavirus that causes Covid-19 from invading cells.

Driven by the pandemics spread, research teams have been screening thousands of drugs to see if they have this unexpected potential to fight the coronavirus. Theyve tested the drugs on dishes of cells, and a few dozen candidates have made the first cut.

Theyre startlingly diverse. Some, like chlorpromazine, have been used for years not for viral infections, but for conditions including cancer, allergies, arthritis, even irregular menstrual periods. Other drugs have not yet been approved by the Food and Drug Administration, but they have already proven safe in clinical trials. Their track records might help them get approved faster than a drug designed from scratch.

As researchers publish findings on these promising drugs, theyre starting tests on animals and people to see how well they perform. No one should try self-medicating with any of the drugs for Covid-19, the researchers warned, since they may have dangerous side effects and have yet to be proven effective in clinical trials.

Im going to be brutally honest with you: 95 to 98 percent of these are going to fail, said Sumit K. Chanda, a virologist at Sanford Burnham Prebys Medical Discovery Institute in La Jolla, Calif. But we only need one or two.

The strategy Dr. Chanda and other researchers are using is known as drug repurposing. It has a history that started decades before Covid-19 appeared. In 1987, for example, the cancer drug zidovudine became the first F.D.A.-approved drug against H.I.V.

The most obvious drugs to repurpose against the new coronavirus are those that work against other viruses. One high-profile antiviral being investigated is remdesivir, which Gilead Sciences previously tested unsuccessfully as an antiviral against Ebola.

But over the years, researchers have found some drugs that originally had nothing to do with viruses turn out to be good antivirals, too. Its just hard to tell in advance which ones have this hidden power.

We dont know a lot about why drugs do what they do, said Matthew Frieman, a virologist at the University of Maryland School of Medicine.

In 2012, another coronavirus disease known as MERS emerged in the Middle East. Dr. Frieman responded by starting a drug-repurposing study. He and his colleagues tested 290 F.D.A.-approved drugs and found that 27 of them blocked the MERS virus from infecting cells. They also proved effective against the related coronavirus that causes SARS.

Dr. Frieman and his colleagues have now tested those drugs against the new coronavirus, and made a preliminary report that 17 of them showed promise. Along with chlorpromazine, they include drugs for disorders as varied as Parkinsons disease and leukemia.

Recently, Dr. Chandas team in California began a mammoth search of their own for drugs to repurpose for Covid-19. They doused infected cells with 13,000 compounds and looked for ones that slowed down the virus. They then narrowed down these candidates by reducing their doses, in order to mimic the levels that would end up in a patients lungs.

On April 17, Dr. Chandas team reported in a preprint, which has not yet been peer-reviewed by a journal, that six drugs showed particular promise, including one for osteoporosis and one thats been investigated as treatment for arthritis.

Yet another team has been trying to find drugs that work against coronavirus and also to learn why they work.

The team, led by Nevan Krogan at the University of California, San Francisco, has focused on how the new coronavirus takes over our cells at the molecular level.

The researchers determined that the virus manipulates our cells by locking onto at least 332 of our own proteins. By manipulating those proteins, the virus gets our cells to make new viruses.

Dr. Krogans team found 69 drugs that target the same proteins in our cells the virus does. They published the list in a preprint last month, suggesting that some might prove effective against Covid-19.

The researchers shipped the compounds to the Icahn School of Medicine at Mount Sinai in New York and at the Pasteur Institute in Paris. Those labs tried them out on infected cells.

Brian Shoichet, a pharmaceutical chemist at U.C.S.F. who helped build the list, was keenly aware of how often drug repurposing fails.

I wasnt that hopeful at all, he said.

It turned out that most of the 69 candidates did fail. But both in Paris and New York, the researchers found that nine drugs drove the virus down.

The things were finding are 10 to a hundred times more potent than remdesivir, Dr. Krogan said. He and his colleagues published their findings Thursday in the journal Nature.

Strikingly, the drugs hit only two targets.

One group temporarily stops the creation of new proteins inside cells. This group includes molecules that are being tested as cancer drugs, such as ternatin-4 and Zotatifin.

Dr. Shoichet speculated that these compounds starve the virus of the proteins it needs to make new copies of itself. This attack may suddenly halt the viral production line.

Viruses are actually delicate beasts, he said.

The other compounds home in on a pair of proteins known as Sigma-1 and Sigma-2 receptors. These receptors are part of the cells communication network, helping the cell withstand stress in its environment.

Why does the new coronavirus need to manipulate Sigma receptors? We dont really know, Dr. Shoichet said.

One possibility is that the virus uses Sigma receptors to make a cell produce more of the oily molecules that form membranes for new viruses.

Among the substances that act on Sigma receptors and block the virus, the researchers found, are the hormone progesterone and the drugs clemastine and cloperastine, both used against allergies.

In addition, Dr. Krogan said that all of Dr. Friemans candidates, including chlorpromazine, target Sigma receptors. A third of Dr. Chandas candidates do too, he said.

The researchers also tested dextromethorphan, a Sigma-receptor-targeting drug in many brands of cough syrup. They were surprised to find that, at least in their cell samples, it actually made infections of this coronavirus worse.

In their paper, the researchers raised the possibility that Covid-19 patients may want to avoid dextromethorphan. Dr. Krogan emphasized that more study would be needed to see if it actually increases coronavirus infection in humans. But if it was me, he said, to be cautious, I would not be taking these cough syrups.

The anti-malaria drugs chloroquine and hydroxychloroquine act on the Sigma receptor. Dr. Krogans team found that they also fought the virus in cells. Those compounds were extolled by President Trump for weeks despite no firm evidence they actually helped cure Covid-19.

Dr. Frieman and Dr. Chanda also found that chloroquine-related drugs worked fairly well in slowing the virus in cell cultures. But Dr. Chanda found they didnt work as well as the six compounds at the top of his list.

Dr. Chanda expressed skepticism about the chloroquine drugs, noting their failure against other viruses.

Weve been down this road multiple times, he said. I would happy to be wrong about this.

Last week, the F.D.A. issued a warning against using hydroxychloroquine or chloroquine for Covid-19 outside the hospital setting or a clinical trial. Thats because the drug has a well-known risk for causing irregular heart rhythms.

In their new study, Dr. Krogan and his colleagues ran an experiment that might explain this risk at the molecular level.

They found that chloroquine and hydroxychloroquine bind not just to Sigma receptors, but to a heart protein called hERG, which helps control heartbeats.

I think its a rational argument, said Dr. Frieman, who was not involved in the Nature study. Chloroquine does a lot of things in the cell.

Dr. Krogan and his colleagues found that other compounds target Sigma proteins in a more promising way.

An experimental anticancer compound called PB28 is 20 times more potent than hydroxychloroquine against the coronavirus, for example. But its far less likely to grab onto the hERG protein.

Dr. Chanda said that PB28 in particular looks really fantastic.

Dr. Krogan said that studies are underway to test the drug in hamsters to see if that promise holds. Dr. Frieman and his colleagues are starting animal studies of their own, as well as testing drugs on a chip lined with human lung cells.

Timothy Sheahan, a virologist at the University of North Carolina who was not involved in the new studies cautioned that it will take more testing to make sure these promising drugs are safe to give to patients ravaged by Covid-19.

Cancer drugs, for example, can be like a sledgehammer to your body, he noted. Are you going to want to do that when someone is really sick?

In addition to animal tests and clinical trials, researchers are now planning to tweak the structure of these drugs to see if they can work even more effectively against the virus.

Read more here:

Old Drugs May Find a New Purpose: Fighting the Coronavirus - The New York Times

Taking the fight to superbugs – Times Higher Education (THE)

Antimicrobial resistance is a global health threat that requires international collaboration between researchers from multiple disciplines

Around the world, millions of people are at risk of contracting infections and illnesses that cannot be treated becausethe causative agents superbugs are resistant to medicines. Antimicrobial resistance (AMR) in which bacteria, parasites, viruses and fungi have developed ways to survive treatments that once killed them is a serious threat to global public health.

At the University of Bristol, researchers from numerous disciplines are working together to understand and control AMR in an effort to save lives at home and abroad. The majority of the worlds efforts to address AMR are around bacteria, says Matthew Avison, a professor of molecular bacteriology at the universitys School of Cellular and Molecular Medicine. In the UK, E. coli causes more deaths than any other bacterium, he says. Over time, it has adapted and becomeresistant to the drugs that doctors had previously used to treat it.

His team investigates E. coli, among other pathogenic bacteria. But simply understanding a bacteriums structure and behaviour is not enough.

Our successes are really due to our work with other disciplines, Professor Avison says. Our discoveries, which would otherwise be fairly basic regarding the behaviour of bacteria, can be applied to useful things.

Professor Avison leads the Bristol AMR interdisciplinary research network, funded by the Wellcome Trust. At Bristol, were good at interdisciplinary work, he says. Because the geography of the university is relatively small, and were close to other departments and schools, we can physically interact with each other.

This is how he and his team came to work with a group of physicists and be instrumental in spinning out a company. There are ways you can visualise and collect data with instrumentation that we in the biological sciences arent familiar with, he says. There were physicists at Bristol, however, who were experts in optics and, through collaboration, developed a device that can visualise individual bacteria and watch them move.

This invention has important implications for testing whether bacteria are resistant to a specific antibiotic. Bacteria move differently in the presence of antibiotics, Professor Avison says. If the antibiotics are working and killing them, the bacteria eventually stop moving.

The bacteriologists supplied the physicists with antibiotics and bacteria, while the physicists provided an imaging technique not initially developed for use in the biological sciences. This technique, Total Internal Reflection Microscopy (TIRM), is the cornerstone of Vitamica, a spin-out company specialising in rapid AMR diagnostics, and is now being trialled in hospitals, testing bacteria in patients urine. TIRM can image how the bacteria behave when in the presence of a specific antibiotic: if they do not die, then they are resistant to that drug.

The reason why its so good is that its rapid, says Profesor Avison. You put a sample in and, in less than an hour, you can tell if the antibiotic will work or not. He reiterates that it is still being trialled, but that it is a potentially very important technology in the fight against AMR.

Another vital collaboration for Professor Avison is with colleagues in veterinary science. Kristen Reyher heads the AMR Force, a research group within the Bristol Vet School that examines key topics about veterinary AMR.

In our projects, weve tried to lead with behaviour and social science, she says. We realised that you can have the best solutions and know all the technical answers, but still not be able to change the situation because you arent communicating in the right way.

One recent project spearheaded a method of farmer peer-to-peer learning, to try and change their behaviour with respect to antibiotics. As a vet, I think about disease all day, every day, Dr Reyher says. I dont think about the myriad things that farmers have to balance, but their peers do. They are the best people to listen and challenge one another to be the best stewards of these important medicines.

This awareness of context is fundamental to Bristol researchers AMR efforts. Maria Paula Escobar, another researcher at Bristol Vet School, is interested in how farmers in different countries use antibiotics and how this has an impact on AMR. She has projects in Colombia and collaborates with Dr Reyher and Professor Avison on one in Argentina.

There is a perception that countries just need more time and more money to address excessive antibiotic usage through targets, says Dr Escobar. This lacks an understanding of the different cultural contexts in which antibiotics are used. Antibiotics are not always used for the same reasons and those involved are not always veterinarians and farmers. In Europe, you cannot get hold of an antibiotic if a veterinarian has not prescribed it. That is not the case in many countries.

Bristol researchers also have AMR projects in Thailand, China, sub-Saharan Africa and more. Were not just looking at this as a UK problem, Professor Avison says. Low-income communities, particularly in developing countries, are disproportionately affected by healthcare problems, including AMR. Overcrowding and poor sanitation, for example, are driving infections, and people cant get access to new antibiotics [that would fight resistant infections] they are stuck with the old ones.

And a global problem, such as AMR, requires global collaboration. We couldnt do our work [in other countries] without great collaborations with local researchers, Professor Avison says. All of the work we do involves people going out and collecting samples from farms, from the environment, from people, which is done by researchers in those countries.

Training local researchers is part of this support, he says. These skills are becoming increasingly vital in an age of AMR a problem which will never go away entirely.

I dont think well ever solve the problem, Professor Avison concludes. Bacteria are very adaptable. They will always evolve and come back to us. That is why researchers have to be adaptable, too.

Find out more about the University of Bristol.

Read the original here:

Taking the fight to superbugs - Times Higher Education (THE)

CU Anschutz Researchers Win Grant to Study Covid-19 Effects on Heart – CU Anschutz Today

A team of CU Anschutz researchers, along with scientists at the Cleveland Clinic, the Mayo Clinic, Stanford University and others, have won a grant from the American Heart Association (AHA) to investigate the effects of Covid-19 on the bodys cardiovascular and cerebrovascular systems.

The Covid-19 and Its Cardiovascular Impact Rapid Response Grant received over 750 proposals from institutions around the nation, one of the largest responses the AHA ever had to a single topic request for applications. The association awarded $1.2 million to teams at 12 of those institutions, including CU Anschutz.

Despite extensive evidence of clinically important cardiac involvement in some Covid-19 patients, virtually nothing is known about how the virus is affecting the heart and why patients with a history of heart problems are more at risk, said Michael Bristow, MD, PhD, professor of cardiology and leader of the team from the CU School of Medicine. We dont even know if the virus can directly infect heart muscle cells.

But based on work done in his lab over the last 15 years, Bristow and his team know that the receptor the Covid-19 virus binds to is increased in abnormal heart muscle and other mechanisms may be responsible for patients with histories of heart problems being more susceptible to the cardiac effects of Covid.

In this study of Covid-19 patients with evidence of cardiac involvement with catheters, well be taking samples of the heart muscle, measuring the amount as well as the cell-localization of the virus, Bristow said. Well then investigate how the virus is altering the hearts histologic and molecular makeup. Hopefully, these findings will set the stage for more specific treatment of cardiac involvement in COVID-19 disease.

The other team members include: Natasha Altman, MD, Cardiology; John Messenger, MD, Cardiology; Edward Gill, MD, Cardiology; Thomas Campbell, MD, Infectious Diseases and Amber Berning, MD, Pathology.

The Cleveland Clinic will serve as the initiatives COVID-19 Coordinating Center. A team from this center will collect results from the research projects and coordinate the dissemination of all study findings.

Several of these studies focus on disparity and underserved populations and many with pre-existing conditions and thats critical because were seeing these people coming in sicker and getting sicker faster from the complications of COVID-19 and we need to understand whats causing that and how we can help them, said American Heart Association president Robert A. Harrington, M.D., FAHA, Arthur L. Bloomfield Professor of Medicine and chair of the department of medicine at Stanford University.

The research projects are considered fast-tracked to report results as quickly as possible to address the COVID-19 crisis. Research will get underway as early as June 1, with findings expected in less than six to nine months for most of the studies. Several researchers aim to have actionable outcomes before a new anticipated wave of COVID-19 strikes in the winter.

Here is the original post:

CU Anschutz Researchers Win Grant to Study Covid-19 Effects on Heart - CU Anschutz Today

Premier League stars with coronavirus symptoms to have lung and heart tests before return – Mirror Online

Premier League players who have suffered COVID-19 symptoms will undergo additional testing for potential lung and heart problems as part of the return-to-play protocol.

Top-flight teams will discuss on Friday the detailed proposals to allow a phased return to small group sessions and then normal squad training before a proposed June restart.

The new rules include players needing to wear face masks or snoods in training and all footballs to be disinfected.

But before this Training Return Date, all clubs must undertake a risk assessment of every player for potential respiratory and/or cardiac complications associated with COVID-19.

For players who are suspected or confirmed sufferers, the preferred testing will see doctors in PPE carrying out blood tests and ECG (electrocardiogram) scans.

The protocol states: All exercise will be stopped until blood results have returned to normal, which may take weeks or months as ongoing elevated blood results may indicate ongoing inflammation and as such risk of sudden arrhythmic death.

Ian Hall, Professor of Molecular Medicine at Nottingham University, said: Groups of individuals, including footballers, who have had COVID19 will include many who had disease which was very mild, with minimal symptoms, and a small number who had more severe disease, potentially resulting in a hospital admission with viral pneumonia.

In general, disease has been more severe in patients who are elderly and have other medical conditions such as high blood pressure, heart disease or chronic lung disease.

"One would therefore expect most premier league footballers who had COVID19 to have had mild forms of the disease.

"I would predict most footballers will not have long term complications if they have had COVID19, but there may be a small number who have some reduction in physical fitness due to having had more severe disease.

"So monitoring simple indicators such as lung function and cardiac function would make sense.

Premier league footballers obviously require high levels of overall fitness, so even a small reduction in lung or heart function could have significant effects on performance.

All players and staff will have to undergo COVID-19 tests at the Premier League's expense within 48 hours of returning to group sessions at the training ground.

Any positive tests will see individuals isolated for seven days before a re-test.

See the article here:

Premier League stars with coronavirus symptoms to have lung and heart tests before return - Mirror Online

Blue Earth Diagnostics CEO Jonathan Allis Appointed Chair of UK Rapid Testing Consortium (UK-RTC) for COVID-19 by UK Department of Health and Social…

OXFORD, England & BURLINGTON, Mass.--(BUSINESS WIRE)-- Blue Earth Diagnostics, a Bracco company focused on molecular imaging diagnostics, today announced that its CEO, Dr Jonathan Allis, has been appointed as Chair of the UK Rapid Testing Consortium (UK-RTC) for COVID-19 by the UK Department of Health and Social Care (DHSC). The UK-RTC has been formed to draw upon the expertise and resources of the UKs life sciences industries in a combined effort to design and develop a home use antibody test to determine whether people have developed antibodies (and perhaps, potential immunity) after contracting and recovering from COVID-19. It combines the science of Oxford University with the development and manufacturing skills of four UK diagnostic companies: Abingdon Health in England, BBI Solutions in Wales, Omega Diagnostics in Scotland and CIGA Healthcare in Northern Ireland. In his role as Chair of the UK-RTC, Dr Allis will serve as an independent liaison between the participating diagnostic companies and the government. The part-time engagement is of a limited duration, during which time Dr Allis will retain his responsibilities as CEO of Blue Earth Diagnostics. The UK-RTC Chair is independent of the diagnostic companies involved, and Blue Earth Diagnostics is not otherwise engaged in this initiative.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200501005100/en/

Jonathan Allis, CEO of Blue Earth Diagnostics (Photo: Business Wire)

When the DHSC invited me to chair a consortium to develop a COVID-19 antibody test based on new technology developed at Oxford University, and in light of the urgency of the COVID-19 health crisis worldwide, I felt it was my absolute duty to say yes, said Jonathan Allis, D. Phil, CEO of Blue Earth Diagnostics. Testing for the presence of the SARS-CoV-2 virus (antigen testing) and immune response after COVID-19 (antibody testing) is possible in large hospital and public and private labs now, but what we really need is a home test (somewhat similar to a home pregnancy test), which can be used to test the whole population. This would help us understand how much of the population has been exposed to the virus and help determine plans for people getting back to work.

Dr Allis continued, Medical diagnostics are critical to informing proper care and treatment for patients, and I feel honoured that my industry experience in the rapid development of healthcare diagnostics may be of value in this effort.

This is a great story of how our manufacturers in the UK are stepping up to the challenge of COVID-19, and I am hopeful that this product will make an impact in our battle against this terrible disease," said Lord Bethell, Health Minister for Innovation and Testing. This is a big step in the right direction. People want to know if theyve had the disease, with a test they can trust.

Jonathan Allis is the founding CEO of Blue Earth Diagnostics. Prior to this role, Dr Allis was the General Manager for PET at GE Healthcare Life Sciences, and had global responsibility for GE Healthcares PET agent and PET synthesis platforms business. He has previously held positions in R&D, Marketing and Product Development at GE Healthcare, Amersham plc, Siemens Medical Solutions and Oxford Magnet Technology, in the UK, USA and Germany.

Dr Allis is Non-Executive Chairman of Polarean Imaging plc and previously served as Co-Chair of the Society of Nuclear Medicine and Molecular Imagings Industry Value Initiative. He has an undergraduate degree in Physics from the University of Cape Town and a doctorate in Biochemistry from the University of Oxford.

About Blue Earth Diagnostics

Blue Earth Diagnostics is a leading molecular imaging diagnostics company focused on the development and commercialization of novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Formed in 2014, Blue Earth Diagnostics is led by recognized experts in the clinical development and commercialization of innovative nuclear medicine products. The companys first approved and commercially available product is Axumin (fluciclovine F 18), a novel molecular imaging agent approved in the United States and European Union for use in PET imaging to detect and localize prostate cancer in men with a diagnosis of biochemical recurrence. Fluciclovine F 18 has a broad range of other potential applications in cancer imaging and Blue Earth Diagnostics is investigating the molecule for other cancers including in neuro-oncology. The company's pipeline includes innovative Prostate Specific Membrane Antigen (PSMA)-targeted radiohybrid ("rh") agents, which are a clinical-stage, investigational class of theranostic compounds, with potential applications in both the imaging and treatment of prostate cancer. Blue Earth Diagnostics is a subsidiary of Bracco Imaging S.p.A., a global leader in diagnostic imaging. For more information, visit: http://www.blueearthdiagnostics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200501005100/en/

Read this article:

Blue Earth Diagnostics CEO Jonathan Allis Appointed Chair of UK Rapid Testing Consortium (UK-RTC) for COVID-19 by UK Department of Health and Social...

Genespire Secures 16 Million Series A Financing from Sofinnova Partners to Advance Transformative Gene Therapies – Yahoo Finance

Biotech executive, Julia Berretta, Ph.D., is named Chief Executive Officer

Genespire, a biotechnology company focused on the development of transformative gene therapies for patients affected by genetic diseases, announced today the successful close of a 16M Series A financing from Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan. The company also announced the appointment of Julia Berretta, Ph.D., as Chief Executive Officer and member of the Board of Directors. Graziano Seghezzi, Managing Partner at Sofinnova Partners, and Lucia Faccio, Ph.D., Partner at Sofinnova Partners, will also join the Board.

Genespire was founded in March 2020 as a spin-off of the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget), one of the worlds leading cell and gene therapy research institutes spearheaded by gene therapy pioneer Prof. Luigi Naldini. The Company was co-founded by Fondazione Telethon and the San Raffaele Hospital, along with Prof. Naldini and Dr. Alessio Cantore.

The funds will be used to advance Genespires leading-edge platform technologies towards the development of novel gene therapies in two main areas: primary immunodeficiencies and metabolic genetic diseases.

"Our mission has always been to develop breakthrough solutions for genetic diseases," said Prof. Naldini, Genespires co-founder and Director of SR-Tiget. "This financing enables the company to translate our innovative science and early stage programs into clinical development. The appointment of Dr. Berretta as CEO is a major reinforcement of our team."

Sofinnova Partners Dr. Faccio added, "Genespire is an exciting investment with all the key ingredients for success: Outstanding scientists that developed the first ex-vivo gene therapy to market, experienced executives brought in through Sofinnova Partners network and game changing technologies that have the potential to impact the lives of patients with genetic diseases."

"I am thrilled to be joining Genespire and such exceptional scientific founders," said Dr. Berretta. "Genespire was born of decades of experience in the gene therapy field, and is optimally positioned to advance transformative therapies for patients affected by severe inherited diseases."

Dr. Berretta was part of the Executive Committee of Cellectis S.A., a Nasdaq-listed clinical stage gene editing company developing CAR-T cell therapies for cancer, where she led business development as well as strategic planning. She is also an independent Board member of Treefrog Therapeutics, an innovative stem cell company.

About Genespire

Genespire is a biotechnology company focused on the development of transformative gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases. Based in Milan, Italy, Genespire was founded in March 2020 by the gene therapy pioneer Prof. Luigi Naldini, Dr. Alessio Cantore, Fondazione Telethon and Ospedale San Raffaele. It is a spin-off of SR-Tiget, a world leading cell and gene therapy research institute and is backed by Sofinnova Partners. http://www.genespire.com

About Sofinnova Partners

Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over 2 billion under management.

For more information, please visit: http://www.sofinnovapartners.com

About Fondazione Telethon

Fondazione Telethon is a non-profit organisation created in 1990 as a response to the appeals of a patient association group of stakeholders, who saw scientific research as the only real opportunity to effectively fight genetic diseases. Thanks to the funds raised through the television marathon, along with other initiatives and a network of partners and volunteers, Telethon finances the best scientific research on rare genetic diseases, evaluated and selected by independent internationally renowned experts, with the ultimate objective of making the treatments developed available to everyone who needs them. Throughout its 30 years of activity, Fondazione Telethon has invested more than 528 million in funding more than 2.630 projects to study more than 570 diseases, involving over 1.600 scientists. Fondazione Telethon has made a significant contribution to the worldwide advancement of knowledge regarding rare genetic diseases and of academic research and drug development with a view to developing treatments. For more information, please visit: http://www.telethon.it

Story continues

About Ospedale San Raffaele

Ospedale San Raffaele (OSR) is a clinical-research-university hospital established in 1971 to provide international-level specialised care for the most complex and difficult health conditions. OSR is part of Gruppo San Donato, the leading hospital group in Italy. The hospital is a multi-specialty center with over 60 clinical specialties; it is accredited by the Italian National Health System to provide care to both public and private, national and international patients. Research at OSR focuses on integrating basic, translational and clinical activities to provide the most advanced care to our patients. The institute is recognized as a global authority in molecular medicine and gene therapy, and is at the forefront of research in many other fields. Ospedale San Raffaele is a first-class institute which treats many diseases and stands out for the deep interaction between clinical and scientific area. This makes the transfer of scientific results from the laboratories to the patients bed easier. Its mission is to improve knowledge of diseases, identify new therapies and encourage young scientists and doctor to grow professionally. For more information, please visit: http://www.hsr.it

About the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget)

Based in Milan, Italy, the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) is a joint venture between the Ospedale San Raffaele and Fondazione Telethon. SR-Tiget was established in 1995 to perform research on gene transfer and cell transplantation and translate its results into clinical applications of gene and cell therapies for different genetic diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200429005417/en/

Contacts

Julia BerrettaCEO, Genespire S.r.linfo@genespire.com +39 02 83991300

Bommy LeeHead of Communications, Sofinnova Partnersblee@sofinnovapartners.com +33 (0) 6 47 71 38 11

North AmericaRooneyPartners LLCKate Barrettekbarrette@rooneyco.com +1 212 223 0561

FranceStrategiesImage (S&I)Anne Reinanne.rein@strategiesimage.com +33 6 03 35 92 05

Read the original post:

Genespire Secures 16 Million Series A Financing from Sofinnova Partners to Advance Transformative Gene Therapies - Yahoo Finance